SCHEMBL2090934

SCHEMBL2090934

O=C(O)Nc1cccc(F)c1

nearest known ligand 0.69

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.69
KMT2A Q03164 4/20 0.69
RAB9A P51151 2/20 0.68
NPC1 O15118 1/20 0.68
HPGD P15428 1/20 0.68
TSHR P16473 1/20 0.62
KCNK3 O14649 1/20 0.59
MMP1 P03956 1/20 0.58
MMP2 P08253 1/20 0.58
MMP9 P14780 1/20 0.58
GFER P55789 1/20 0.58
HTT P42858 2/20 0.57
MTOR P42345 2/20 0.56
GAA P10253 1/20 0.56
TAAR1 Q96RJ0 1/20 0.56
MAPT P10636 1/20 0.55
ALDH1A1 P00352 1/20 0.55
POLB P06746 1/20 0.55
TDP1 Q9NUW8 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30130671 1.00 MEN1 (0.69) MEN1KMT2ARAB9ANPC1HPGD
Hydrochloric Acid SCHEMBL11459054 0.98 MEN1 (0.67) MEN1KMT2ARAB9ANPC1HPGD
SCHEMBL27193042 0.85 RAB9A (0.79) MEN1KMT2ARAB9ANPC1HPGD
SCHEMBL30851500 0.85 RAB9A (0.79) MEN1KMT2ARAB9ANPC1HPGD
SCHEMBL11858223 0.84 GPR35 (0.67) MEN1KMT2ATSHRKCNK3GAA
SCHEMBL4555389 0.84 KMT2A (0.72) MEN1KMT2ARAB9ANPC1HPGD
SCHEMBL10883410 0.84 GPR35 (0.74) MEN1KMT2ARAB9ANPC1HPGD
SCHEMBL2090931 0.83 MEN1 (0.69) MEN1KMT2ARAB9ANPC1HPGD
SCHEMBL687148 0.82 GAA (0.68) MEN1KMT2ARAB9ANPC1HPGD
SCHEMBL167713 0.82 MEN1 (0.67) MEN1KMT2ARAB9ANPC1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1893200-B1 CARBAMATE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX PHARMACEUTICALS SA (CH) 2010-09-29 EP claimed
WO-2009087220-A1 USE OF THIAZOLOIMIDAZOLES, THIAZOLOTETRAZOLES AND THIAZOLOTRIAZOLES AS MGLUR5 ANTAGONISTS GLAXO GROUP LIMITED (GB) 2009-07-16 WO claimed
WO-2009087218-A1 THIAZOLTRIAZOLES AND THIAZOLIMIDAZOLES AS ANTAGONISTS OF THE MGLUR5 RECEPTOR GLAXO GROUP LIMITED (GB) 2009-07-16 WO claimed
US-20090082399-A1 Carbamate derivatives as positive allosteric modulators of metabotropic glutamate receptors ADDEX PHARMA SA (CH) 2009-03-26 US claimed
EP-1212295-B1 SUBSTITUTED ALPHA-HYDROXY ACID CASPASE INHIBITORS AND THE USE THEREOF CYTOVIA INC (US) 2008-10-01 EP claimed
EP-1893200-A2 CARBAMATE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX Pharma S.A. (CH) 2008-03-05 EP claimed
EP-1799673-A1 PYRAZOLE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS Memory Pharmaceuticals Corporation (US) 2007-06-27 EP claimed
US-7166587-B2 Carbamic acid alkyl ester derivatives HOFFMANN-LA ROCHE INC. (US) 2007-01-23 US claimed
WO-2006123244-A2 CARBAMATE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX PHARMA SA (CH) 2006-11-23 WO claimed
US-20060154960-A1 Phosphodiesterase 4 inhibitors MEMORY PHARMACEUTICALS CORPORATION 2006-07-13 US claimed
WO-2006044528-A1 PYRAZOLE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2006-04-27 WO claimed
CN-1235875-C Substituted alpha-hydroxy acid caspase inhibitors and uses thereof CYTOVIA INC (US) 2006-01-11 CN claimed
US-20050075327-A1 Carbamic acid alkyl ester derivatives HOFFMAN-LA ROCHE INC. 2005-04-07 US claimed
EP-1494700-A2 CASPASE INHIBITORS FOR THE TREATMENT OF DISEASES AND CONDITIONS CAUSED BY EXPOSURE TO RADIONUCLIDES, BIOLOGICAL AGENTS, OR CHEMICAL AGENTS Cytovia, Inc. (US) 2005-01-12 EP claimed
WO-2004002401-A2 CASPASE INHIBITORS FOR THE TREATMENT OF DISEASES AND CONDITIONS CAUSED BY EXPOSURE TO RADIONUCLIDES, BIOLOGICAL AGENTS, OR CHEMICAL AGENTS CYTOVIA, INC. (US) 2004-01-08 WO claimed
CN-1382119-A Substituted alpha-hydroxy acid caspase inhibitors and uses thereof CYTOVIA INC (US) 2002-11-27 CN claimed
EP-4323338-A1 TEAD INHIBITORS Orion Corporation (FI) 2024-02-21 EP disclosed
US-20230027752-A1 OPIOID RECEPTOR AGONIST, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF FUDAN UNIVERSITY (CN) 2023-01-26 US disclosed
CN-1382119-A Substituted alpha-hydroxy acid caspase inhibitors and uses thereof CYTOVIA INC (US) 2002-11-27 CN disclosed
US-5866596-A DRUGS WITH ANTIINFLAMMATORY AND ANALGESIC PROPERTIES. LABORATORIES UPSA (FR) 1999-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050075327-A1 Carbamic acid alkyl ester derivatives BCHE, CHRM1, ADCY7 MEN1 1340/4885KMT2A 2212/4885RAB9A 83/4885
US-20090082399-A1 Carbamate derivatives as positive allosteric modulators of metabotropic glutamate receptors GRM5, GRIK5, GRM1 MEN1 4636/4885KMT2A 1223/4885RAB9A 723/4885
US-20230027752-A1 OPIOID RECEPTOR AGONIST, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF OPRM1, OPRD1, OPRL1 MEN1 4579/4885KMT2A 1648/4885RAB9A 1910/4885
US-20060154960-A1 Phosphodiesterase 4 inhibitors PDE4A, PDE4B, PDE12 MEN1 4070/4885KMT2A 1669/4885RAB9A 1437/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.